Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupEndocrine and Neuroendocrine OncologyGastroenterologic OncologyGynecological OncologyHead and Neck OncologyThoracic TumorsTumor, regardless of entityDiseaseLung Carcinoma, Non-Small CellThyroid CancerTumor Biomarker DefinedSubgroupHER2+Mismatch Repair - deficient / Microsatellite Instability - high (dMMR/MSI-H)NTRK Gene FusionRET fusion positiveTMB - Tumor Mutational Burden highICD10C34.-C73MeSHNeoplasmsThyroid NeoplasmsSequenceChemotherapyChemo-substanceEntrectinibLarotrectinibPembrolizumabSelpercatinibTrastuzumab emtansineChemo-substanceEntrectinibLarotrectinibPembrolizumabSelpercatinibTrastuzumab emtansineChemo-substanceEntrectinibLarotrectinibPembrolizumabSelpercatinibTrastuzumab emtansineChemo-substanceEntrectinibLarotrectinibPembrolizumabSelpercatinibTrastuzumab emtansineNo. Substances1 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionGranisetronSupportive substanceBalanced Crystalloid SolutionGranisetronSupportive substanceBalanced Crystalloid SolutionGranisetronSupportive substanceBalanced Crystalloid SolutionGranisetronNo. Substances12Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationRefractory diseaseSecond lineseveral possibleTherapy phaseTherapy intentionpalliativeRisksAdrenal InsufficiencyAnemia Hb below 8g/dlAnemia Hb below 10g/dlAstheniaColitisConstipationDiarrheaDyspneaEdemaEmetogenicityEmetogenicity (MASCC/ESMO)Gastrointestinal ToxicityHeadacheHepatotoxicityHypertensionHyponatremiaIncrease AminotransferasesInfectionsLymphopeniaNauseaNeuropathyNeutropeniaPneumonitisPyrexiaQTc Time ExtensionRashSepsisThrombocytopenia below 50 000/µlVomiting only studiesPublicationAuthorDoebele RDrilon AJhaveri KLLe DTMarabelle ADiseaseLokal fortgeschrittener, nicht resezierbarer oder metastasierter solider Tumor, TMB-hoch, mindestens 1 Vortherapielinie, ECOG 0-1lokal fortgeschrittener oder metastasierter Tumor, unabhängig von der Entität, NTRK-Genfusion, ECOG 0-3Metastasierte, refraktäre, progrediente Mismatch-Repair Deficiency Karzinome, ECOG 0-1RET-bedingte Tumoren, Zweitlinie oder höher, ECOG 0-2Solide Tumoren HER2 amplifiziert, außer Mamma-Ca oder AEG-Tumoren und Magen-Ca, ECOG 0-1Solide Tumoren mit NTRK-Fusion, TKI-naiv, ECOG 0-2OriginDivision of Medical Oncology, University of Colorado, Aurora, CO, USAJohns Hopkins Sidney Kimmel Comprehensive Cancer Center, BalimoreMemorial Sloan-Kettering Center, New York, USA, NCI-MATCH trial (EAY131)Memorial Sloan Kettering Cancer Center, 1275 York Ave., New YorkMemorial Sloan Kettering Cancer Center and Weill Cornell Medical College, LIBRETTO-001Universite Paris-Saclay, Villejuif, France, KEYNOTE-158Protocols in Revision 6 protocols foundProtocols under revision.Entrectinib 600, Tumor Biomarker Defined (PID758)Larotrectinib 100, Tumor Biomarker Defined (PID1314)Pembrolizumab 200, Tumor Biomarker Defined (PID1704)Pembrolizumab 400, Tumor Biomarker Defined (PID1286)Selpercatinib 160, Tumor Biomarker Defined (PID1732)Trastuzumab Emtansine 3.6, Tumor Biomarker Defined (PID1677)